References
- Duong HK, Savani BN, Copelan E, et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2014;20: 1262–1273.
- Lefrère F, Bernard M, Audat F, et al. Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell (PBSC) collection: a retrospective study of 126 patients. Leuk Lymphoma 1999;35:501–505.
- Kopf B, De Giorgi U, Vertogen B, et al. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization. Bone Marrow Transplant 2006;38:407–412.
- Ataergin S, Arpaci F, Turan M, et al. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Am J Hematol 2008;83:644–648.
- Ria R, Reale A, Melaccio A, et al. Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies. Clin Exp Med 2015;15:145–150.
- Lefrère F, Brignier AC, Elie C, et al. First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor. Adv Ther 2011;28:304–310.
- Manko J, Walter-Cronecka A, Jawniak D, et al. A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization. Pharmacol Rep 2014;66: 239–244.
- Sivgin S, Karakus E, Kaynar L, et al. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey. Transfus Apher Sci 2013;48:315–320.
- Cesaro S, Tridello G, Prete A, et al. Biosimilar granulocyte- colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients. Transfusion 2015;55:246–252.
- Publicover A, Richardson DS, Davies A, et al. Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. Br J Haematol 2013;162:107–111.
- Schmitt M, Publicover A, Orchard KH, et al. Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation. Theranostics 2014;4:280–289.
- Romeo A, Chierichini A, Spagnoli A, et al. Standard-versus high-dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilization. Transfusion 2010;50: 2432–2446.
- Olivieri A, Marchetti M, Lemoli R, et al. Proposed definition of “poor mobilizers” in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianti di Midollo Osseo. Bone Marrow Transplant 2012;47:342–351.
- Cheng J, Schmitt M, Wuchter P, et al. Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma. Transfusion 2015;55:275–283.
- Mattii L, Battolla B, Azzarà A, et al. Glycosylation interference on RhoA activation: focus on G-CSF. Leuk Res 2011;35:265–267.